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Abstract
Although the rapid spread of carbapenemase-producing Gram-negatives (CPGNs) is providing the scientiﬁc community with a great deal
of information about the molecular epidemiology of these enzymes and their genetic background, data on how to treat multidrug-resis-
tant or extended drug-resistant carbapenemase-producing Enterobacteriaceae and how to contain their spread are still surprisingly
limited, in spite of the rapidly increasing prevalence of these organisms and of their isolation from patients suffering from life-threatening
infections. Limited clinical experience and several in vitro synergy studies seem to support the view that antibiotic combinations should
be preferred to monotherapies. But, in light of the data available to date, it is currently impossible to quantify the real advantage of drug
combinations in the treatment of these infections. Comprehensive clinical studies of the main therapeutic options, broken down by
pathogen, enzyme and clinical syndrome, are deﬁnitely lacking and, as carbapenemases keep spreading, are urgently needed. This spread
is unveiling the substantial unpreparedness of European public health structures to face this worrisome emergency, although experiences
from different countries—chieﬂy Greece and Israel—have shown that CPGN transmission and cross-infection can cause a substantial
threat to the healthcare system. This unpreparedness also affects the treatment of individual patients and infection control policies, with
dramatic scarcities of both therapeutic options and infection control measures. Although correct implementation of such measures is
presumably cumbersome and expensive, the huge clinical and public health problems related to CPGN transmission, alongside the
current scarcity of therapeutic options, seem to fully justify this choice.
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Introduction
The rapid spread of carbapenemase-producing Gram-nega-
tives (CPGNs) is providing the scientiﬁc community with a
great deal of information about the molecular epidemiology
of carbapenemases and their genetic background. At the
same time, this spread is unveiling the substantial unpre-
paredness of European public health structures to face this
worrisome emergency. This unpreparedness equally affects
the treatment of individual patients and infection control pol-
icies, with dramatic scarcities in both therapeutic options
and infection control measures.
Clinical and Therapeutic Issues
Carbapenemase production is normally associated with
generalized resistance to carbapenems, penicillins and cepha-
losporins, and these strains usually also harbour mechanisms
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of resistance to aminoglycosides and quinolones. This multi-
drug resistance often leaves tigecycline (apart from the treat-
ment of Pseudomonas spp.) and colistin as the only agents
available.
Preclinical data
The few compounds to which carbapenemase-producing
non-fermenters most often prove susceptible in in vitro tests
have been used in time-kill studies and animal models of
infections with these pathogens, but, overall, the resulting
data are limited and rather patchy.
Aztreonam administered in high doses was found to sig-
niﬁcantly decrease the viable counts of VIM-2-producing
Pseudomonas aeruginosa in lung tissue of treated rats [1],
but the accuracy of the model is seriously put into ques-
tion by the fact that all of the other b-lactams tested pro-
duced a similar effect, despite their high MICs. In fact,
time-kill studies on 12 metallo-b-lactamase (MBL)-producing
P. aeruginosa isolates performed with aztreonam, either
alone or in combination with ceftazidime and amikacin,
revealed bactericidal activity against one and eight isolates,
respectively, whereas colistin proved to be bactericidal
against all 12 isolates in the same study [2]. The combina-
tion of aztreonam and various other b-lactams was syner-
gistic against four of nine MBL-producing P. aeruginosa
isolates and against four of ﬁve MBL-producing Acinetobac-
ter baumannii isolates, whereas antagonism was noted in
two isolates and one isolate, respectively [3]. In neutrope-
nic mice infected with IMP-type-producing P. aeruginosa,
high-dose polymyxin B, but not imipenem or aztreonam,
signiﬁcantly improved survival as compared with saline-
treated controls [4].
Colistin was bactericidal against nine OXA-58-producing
A. baumannii isolates, and synergism was observed in some of
these isolates with combinations of rifampin and imipenem,
rifampin and ampicillin–sulbactam, or colistin and rifampin
[5].
In a mouse pneumonia model, imipenem was still the best
option for infections caused by A. baumannii with moderate
levels of imipenem resistance, preferably combined with am-
inoglycosides. For isolates that were highly resistant to imip-
enem, a combination of rifampin and imipenem, tobramycin
or colistin proved useful [6].
As the current breakpoints do not classify many carbape-
nemase-producing Enterobacteriaceae as ‘resistant’ to carba-
penems but only as being endowed with reduced
susceptibility to these compounds (MIC £4 mg/L), the addi-
tional problem arises of whether in vivo non-susceptibility
actually predicts in vivo resistance to treatment. Thus, for
these pathogens, carbapenem compounds have also been
considered as potential therapeutic agents in time-kill studies
and animal models of infection.
The activity of imipenem against VIM-1-producing Klebsiella
pneumoniae was evaluated in a thigh infection model in neu-
tropenic mice. The efﬁcacy of imipenem was signiﬁcantly
higher against the control (i.e. non-VIM-1-producing) isolate.
However, a high imipenem dose yielded an appreciable effect
against the VIM-1-producing isolates with a low imipenem
MIC (2–4 mg/L), suggesting the possible usefulness of
increased drug doses against VIM-producing carbapenem-sus-
ceptible isolates [7].
Another study evaluated the efﬁcacy of either carbapen-
ems or aztreonam, in a rabbit model of peritoneal abscess,
by using an extended-spectrum b-lactamase-negative, carba-
penem-susceptible, VIM-1-producing Escherichia coli clinical
isolate (MICs of imipenem, meropenem, ertapenem and azt-
reonam of 1, £0.25, 1.5, and £0.25, respectively). Imipenem,
meropenem, ertapenem or aztreonam showed a statistically
signiﬁcant reduction of viable colonies in treated animals as
compared with controls. Among the three carbapenems, er-
tapenem produced the highest reduction in viable counts,
probably due to a longer time above the MIC. Treatment
with aztreonam resulted in a signiﬁcantly lower mortality
than in controls, and in 26.7% of the animals in the aztreo-
nam group there were no viable colonies after treatment
[8].
In vitro studies have shown a strong inoculum effect with
carbapenems when the susceptibility of VIM-1-producing
K. pneumoniae has been tested [7,9]. The killing activity of
carbapenems against VIM-1-producing K. pneumoniae was
evaluated in two studies. The ﬁrst study considered seven
K. pneumoniae isolates with variable susceptibilities to carba-
penems (MIC range, 1–64 mg/L). Despite initial killing (at
2 h), regrowth was observed with all tested isolates after
24 h of incubation with 8–16 mg/L imipenem, meropenem or
ertapenem, irrespective of the MIC levels. In the same study,
aztreonam exhibited bactericidal activity against all suscepti-
ble isolates [9]. In contrast, in the second study, imipenem
exhibited bactericidal activity against some of the tested
VIM-1-producing K. pneumoniae clinical isolates with MICs £4
mg/L [10].
As far as newer carbapenem compounds are concerned,
in vitro data suggest that doripenem does not offer any
advantage over the older compounds in this class against
many carbapenemase producers [11], with the notable
exception of carbapenem-resistant A. baumannii producing
OXA-58 [12].
Among the non-carbapenem compounds, both tigecycline
and polymyxins have been carefully evaluated, because they
lack cross-resistance with b-lactams.
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The MIC90 of tigecycline for 54 VIM-producing K. pneumo-
niae isolates [13] and for 109 Enterobacteriaceae isolates pro-
ducing MBLs [14] proved to be 2 mg/L, whereas the MIC90
for 104 Enterobacteriaceae isolates producing either MBLs or
KPC-type enzymes [15] and for 95 KPC-producing K. pneu-
moniae isolates [16] was 1 mg/L. In the study of Bratu et al.
[16], tigecycline proved to be bactericidal against two of 16
isolates investigated by time-kill analysis. Resistance to tigecy-
cline is, regrettably, increasing in some geographical areas
such as Greece, as only 65.4% of 50 KPC-producing K. pneu-
moniae strains isolated from Greece during the period 2007–
2008 showed an MIC of £ 2 mg/L [17].
The in vitro activity of colistin for VIM-producing K. pneu-
moniae isolates from Greece has been studied, and the
MIC90 was 16 mg/L (Souli et al., 47th IDSA, 2009, Abstract
218). In the aforementioned study of Bratu et al. [16], poly-
myxin B showed bactericidal activity at 2 and 4 mg/L against
most KPC-producing K. pneumoniae isolates (MIC90, 2 mg/L).
In the aforementioned study by Castanheira et al. [15], poly-
myxin B exhibited an MIC90 of >4 mg/L, and it was active
against 88% of the tested isolates.
Given the scarcity of possible options for monotherapy
and the uncertainty regarding animal data, the effects of anti-
biotic combinations have been studied using both MBL-pro-
ducing and KPC-producing isolates.
The combination of imipenem and colistin has been stud-
ied with a time-kill methodology involving 42 genetically dis-
tinct VIM-1-producing K. pneumoniae isolates from Greek
hospitals. This combination showed synergy against 50% of
colistin-susceptible isolates and against 50% of isolates with
low-level resistance to colistin (MIC, 3–4 mg/L), but it was
antagonistic against 55.6% of colistin-susceptible isolates
(MIC, 2 mg/L). The killing activity was signiﬁcantly better
against isolates susceptible to both agents and isolates non-
susceptible to imipenem but susceptible to colistin [10].
The combination of polymyxin B and either rifampin or
imipenem was tested against 16 KPC-producing K. pneumo-
niae isolates by time-kill analysis. A synergistic effect was
noted for most of the tested isolates, whereas the combina-
tion of polymyxin B (0.5 · MIC) and imipenem was antago-
nistic for three isolates [16].
Fosfomycin was tested by time-kill methodology alone and
in combination with either meropenem, gentamicin or colis-
tin against eight clinical isolates of KPC-producing K. pneumo-
niae. Fosfomycin alone was not bactericidal. All combinations
exhibited indifference, with the exception of the combination
of fosfomycin and meropenem, which showed synergy
against two of the tested isolates (fosfomycin MIC, 16 mg/L;
meropenem MIC, 32–64 mg/L) (Souli et al., 47th IDSA, 2009,
Abstract 218).
A new non-b-lactam b-lactamase inhibitor, NXL104, in
combination with various b-lactam antibiotics, was shown to
be active against KPC-producing Enterobacteriaceae but not
against those producing IMP or VIM metalloenzymes [18–
20]. Although in vitro data are promising, the clinical develop-
ment of this compound is still in its early phases, and the
clinical usefulness remains to be determined. Among the
other promising agents that are also in the early phases of
development are the new carbapenem compound tomope-
nem [21] and various chelating agents, such as hLF1-11 [22].
Clinical data
Studies evaluating potential risk factors for colonization or
infection due to MBL-producing non-fermenters have identi-
ﬁed antibiotic use and prolonged hospital stay as independent
predictors [23,24]. Previous use of either b-lactams [25,26]
or quinolones [25,27] has been identiﬁed as a risk factor.
Analysis of the antimicrobial chemotherapy received by
patients before isolation of MBL-positive strains showed
many of them to have been given non-carbapenem b-lactams.
The frequent co-resistance to other classes of antibiotics
observed in MBL producers, owing to the simultaneous pres-
ence of additional resistance determinants often carried on
integrons, such as genes for aminoglycoside-modifying
enzymes, and/or mutations that upregulate efﬂux systems,
underlines the possibility that MBLs may also be co-selected
by the clinical use of unrelated classes of antibiotics [28].
Nevertheless, it has been emphasized that early recognition
of MBL-producing isolates and rigorous infection control
precautions to prevent their transmission might both be
more important than curbing antibiotic consumption for con-
trolling MBLs in hospitals [26].
Studies evaluating the inﬂuence of MBL production on
mortality in P. aeruginosa infections have revealed higher
mortality rates (hazard ratio 1.55, 95% CI 1.06–2.27), most
likely related to the severity of these infections and to delays
in appropriate antimicrobial therapy [29]. The attributable
mortality of MBL-producing P. aeruginosa bacteraemia in a
Brazilian hospital was reported to be as high as 71.4%, as the
same percentage of patients received inappropriate empirical
therapy [30].
The reported mortality rates associated with infections
caused by MBL-producing Enterobacteriaceae range from
18.8% [31] to 66.7% [32]. Daikos et al. [33] suggested that
the mortality rate in bloodstream infections caused by VIM-
1-producing K. pneumoniae isolates exhibiting an MIC of
4 mg/L was lower than that associated with isolates exhibit-
ing an MIC of >4 mg/L (13.3 vs. 53.8%), but not signiﬁcantly
different from that in the control group of patients infected
with MBL-negative strains. In that report, resistance to
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carbapenems and a high APACHE II score were indepen-
dently associated with mortality.
KPC-producing Enterobacteriaceae infections are usually
systemic and not site-speciﬁc. Risk factors for acquiring infec-
tions with these bacteria include prolonged hospitalization,
intensive-care unit stay, invasive devices, immunosuppression,
and previous use of various antibiotics, including, but not lim-
ited to, carbapenems [34–36]. Both in Israel and in the USA,
a high mortality rate has been attributed to KPC-producing
K. pneumoniae infections, ranging from 38% to 57% [37,38].
A lower attributable mortality (22.2% and 27.8%) was
reported from Greece [17,39]. Mortality has been reported
to be higher for patients infected with imipenem-resistant
KPC-producing Enterobacter spp. than for those infected with
imipenem-susceptible strains [40].
As CPGNs become increasingly prevalent and cause life-
threatening infections, clinical data on optimal treatment are
still surprisingly scarce. Although many studies have focused
on the efﬁcacy of either individual drugs or various combina-
tions against multidrug-resistant (MDR) or even extended
drug-resistant (XDR) non-fermenters, very few have investi-
gated the underlying mechanisms of resistance. Thus, data on
actual carbapenemase producers are limited.
Infections caused by either P. aeruginosa or A. baumannii
producing a carbapenemase pose an enormous challenge,
because these strains are very frequently multiresistant and
are often only susceptible to colistin. In fact, polymyxins have
emerged as the rational clinical option for these infections,
and the successful treatment with colistin of maxillary sinusi-
tis, orbital cellulitis and pneumonia due to MBL-producing
P. aeruginosa in a neutropenic patient has been reported
[41]. However, a recent report of the development of het-
ero-resistance to colistin in an in vitro pharmacokinetic/phar-
macodynamic model seriously put into question the use of
this compound alone as a sound therapeutic option [42].
As compared to monotherapy, combination therapy with
several classes of antibiotics for the treatment of CPGN
infections has shown greater activity and delayed develop-
ment of resistance [43]. A number of recent studies have
shown synergy between rifampin and either colistin or a
carbapenem (including imipenem, meropenem and doripe-
nem). These combinations achieved bactericidal activity at
one-fourth of the MIC for K. pneumoniae, P. aeruginosa and
A. baumannii, even in the presence of resistance to the carba-
penems and rifampin alone [5] (Urban et al., 49th ICAAC,
2009, Abstract E-1447). On an anecdotal basis, the successful
treatment with ciproﬂoxacin and gentamicin of a prosthetic
valve endocarditis due to MBL-producing P. aeruginosa has
been recently reported [44]. The in vitro ﬁndings of another
recent study provide support for the idea that fosfomycin
might be a therapeutic option for the treatment of infections
due to MDR strains of P. aeruginosa [45], but there is only
one published case report of successful treatment of prosta-
titis due to VIM-2-producing P. aeruginosa with the combina-
tion of fosfomycin and aztreonam [46]. Unfortunately,
synergistic effects are strain-speciﬁc, and ad hoc combinations
of drugs must be tested against each clinical isolate in order
to obtain indications of potential usefulness in therapy.
Carbapenemase-producing Enterobacteriaceae often display
an XDR phenotype and, in many cases, the therapeutic
options are extremely limited. In a report from Australia,
however, the majority of Enterobacteriaceae isolates produc-
ing IMP-4 were susceptible to quinolones, and four patients
were successfully treated with this class of agent [47].
Recently, some experience has been gained with tigecy-
cline in the treatment of these infections. Tigecycline has
been used either alone or in combination with another agent
in a limited number of patients. Among six patients with
pneumonia or bloodstream infections, two patients treated
with tigecycline combined with polymyxin B or E survived,
another three had an unfavourable outcome, and one had
microbiological failure and an uncertain clinical outcome
[48]. In an observational retrospective study on the in vivo
efﬁcacy of tigecycline administered as the only active antimi-
crobial for the treatment of infections caused by MDR
pathogens, a successful clinical response was noted in nine of
13 patients (69.2%) infected with MBL-producing Enterobacte-
riaceae (MIC range, 0.019–3 mg/L) [49].
In a case series including 17 seriously ill patients, 12
patients were treated successfully with colistin alone (four
patients) or in combination with either a carbapenem (six
patients) or an active aminoglycoside (two patients) [31]. In
a recent observational study of 67 patients with bloodstream
infection caused by VIM-producing K. pneumoniae [50], 49
(73.1%) received ‘appropriate’ empirical therapy (at least one
agent had proved active in vitro) and 18 (26.9%) ‘inappropri-
ate’ empirical therapy (none of the administered antibiotics
had shown in vitro activity). Among those who received
‘appropriate therapy’, 12 received combination therapy with
two active drugs (nine received meropenem and three imipe-
nem in combination with either colistin (eight patients) or an
active aminoglycoside (four patients)), and 37 received ther-
apy with one active drug (nine meropenem, ﬁve imipenem,
15 colistin, and eight an active aminoglycoside). The lowest
mortality rate (8.3%) was observed in the group of patients
who had received combination therapy with two active
drugs, one of which was a carbapenem and the other of
which was either colistin or an active aminoglycoside,
whereas therapy with one active drug (a carbapenem, colistin
or an aminoglycoside) resulted in a mortality rate (27%)
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similar to that observed in patients who had received
therapy with no active drug (27.8%). Among 18 patients
suffering from a severe infection caused by KPC-producing
K. pneumoniae, 12 (66.7%) were successfully treated with
colistin, either as the only active antimicrobial (six patients)
or in combination with an active aminoglycoside (one
patient), tigecycline (three patients), or a carbapenem in
conjunction with catheter removal (one patient) [17].
The aforementioned study by Falagas et al. [45] has
recently supported the idea of fosfomycin being a possible
therapeutic option for MDR K. pneumoniae. Eleven adult
intensive-care unit patients with infections caused by carba-
penem-resistant K. pneumoniae received intravenous fosfomy-
cin (2–4 g every 6 h) in combination with other antibiotics;
all patients had good bacteriological and clinical outcome of
infection, and none of them experienced fosfomycin-related
adverse events [51].
Carbapenem MICs for carbapenemase-producing Entero-
bacteriaceae are often in the susceptible range, raising the
critical question of whether carbapenems might be active
in vivo for treating infections caused by such organisms.
Anecdotal reports have claimed microbiological and clinical
responses in patients infected with MBL-positive, but in vitro
carbapenem-susceptible, K. pneumoniae strains after treat-
ment with a carbapenem [52], although no details were given
of either doses or administration schedule. On the contrary,
the aforementioned data from Greece [50] showed that
monotherapy with a carbapenem was not superior to inap-
propriate therapy, in terms of 14-day mortality. On the basis
of this experience, it remains doubtful whether monotherapy
with a carbapenem would be effective in the treatment of
such infections. On the other hand, carbapenems in combi-
nation with another active agent (colistin or an aminoglyco-
side) may provide some therapeutic beneﬁt in treating
infections due to VIM-positive carbapenem-susceptible En-
terobacteriaceae.
In this respect, the issue of either reporting such isolates
as fully resistant to carbapenems or taking the respective
MICs at face value should remain open. In a recent study
from the USA [53], frequent (56%) clinical and microbiologi-
cal failures were observed with both imipenem and merope-
nem when they were used to treat infections caused by
K. pneumoniae isolates that yielded imipenem-susceptible
results but were subsequently discovered to be KPC-positive
by PCR. Three of the unsuccessfully treated patients had tra-
cheobronchitis; thus, residual colonization after therapy
could not be excluded. In seven of ten patients whose iso-
lates were initially reported as carbapenem-resistant, treat-
ment with either tigecycline or an aminoglycoside was
successful. Meropenem monotherapy was successful in one
additional patient, giving a success rate of 80%. It is difﬁcult
to draw signiﬁcant conclusions, owing to the small number
of patients and to the retrospective nature of the study;
however, the data are in overall accordance with previous
reports.
Infection Control
Experiences from different countries—with special refer-
ence to Greece [33] and Israel [54]––have shown that
CPGN transmission and cross-infection can be responsible
for increased adverse outcomes, with a substantial threat
to the healthcare system. Unfortunately, the lack of ade-
quate and timely reaction has also been commonly
observed.
Suggested control measures differ substantially between
settings with sporadic occurrence or complete absence of
CPGNs and countries with ongoing CPGN outbreaks or
endemic CPGNs. The suggested control plan is mostly
generic, and can be applied to any threatening MDR bacte-
rium associated with high case-fatality rates, and that has a
high potential for spread in healthcare settings and then
further into the community. The rationale for the plan is
that early detection and intervention has a much higher
likelihood of aborting the eminent epidemic; although this
requires a preparedness plan and resource allocation, in
the long term it is much less costly than confronting an
epidemic. When endemicity has been established, a region-
ally coordinated effort is required in order to contain the
epidemic.
Settings with sporadic occurrence or complete absence of
CPGNs
Efﬁcient CPGN control mandates that a preparedness plan
has been developed and implemented for different healthcare
settings, so as to enable the initiation of urgent and rapid
action when a ﬁrst case has been detected and microbiologi-
cally conﬁrmed. The overall focus of infection control mea-
sures in these settings should be complete eradication,
according to the classic ‘search and destroy strategy’, which
is based on concepts that have been previously described
[55,56]. However, this approach needs to be tailored to the
local CPGN epidemiology.
Reliable detection of the ﬁrst index case in a given region
or hospital is crucial for the implementation of timely inter-
ventions. Microbiological detection may be challenging [28];
thus, all microbiology laboratories should have a highly sensi-
tive screening method in place. If this crucial step is over-
looked, the detection of CPGN clusters will be delayed,
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leading to difﬁcult-to-eradicate outbreaks, as has already
been observed in several countries (Wendt et al., 19th Soci-
ety of Healthcare Epidemiology of America Scientiﬁc Meet-
ing, 2009, Abstract 365). A reference laboratory should
provide back-up support, with rapid conﬁrmation of sus-
pected CPGN cases. Communication channels should be
established in advance, in order to facilitate rapid notiﬁcation
and feedback.
Throughout Europe, active screening policies need to be
clearly established, by deﬁning patients at high risk of CPGN
carriage or infection. At this moment, these risk factors
mainly consist of previous contacts with medical facilities––
such as hospitals, dialysis units, or long-term-care facilities
[57]––with known ongoing outbreaks of CPGNs. For these
patients, pre-emptive isolation while the screening results
are awaited is highly recommended.
The primary surveillance screening site is the stool or rec-
tal swab; limited data indicate that surveillance screening of
stool specimens, rectal swabs or perirectal swabs might pro-
duce higher yields than testing of other body sites (e.g. nares
or skin) [58]. In patients with indwelling devices, specimens
from the related site should also be screened. Skin swabs,
urine and sputum could also be checked in certain patient
groups, e.g. patients with chronic wounds, indwelling urinary
catheters, or endotracheal intubation.
An action plan for rapid implementation of infection con-
trol measures should include all items listed in Table 1.
Isolation precautions should be implemented and strictly
applied, although, in several settings, simple contact isolation
was not sufﬁcient to stop local outbreaks (Schechner V,
TASMC Cre Group, 48th ICAAC and 46th IDSA, 2008,
Abstract K-3508) [59], and cohorting of patients with a dedi-
cated staff is warranted. Long-term follow-up should be pro-
vided, with re-admission alerts of identiﬁed CPGN carriers.
Timely dissemination of information at both the local level
and the national level is a cornerstone for early response. As
things stand now, there is no strong evidence in favour of
using either topical or systemic antibiotic decolonization
treatment.
Settings with endemic CPGNs or ongoing regional out-
breaks
Once CPGNs have become prevalent in a given region or
country, stringent control measures may become more cum-
bersome and expensive. Nevertheless, considering the huge
clinical and public health problems related to CPGN trans-
mission, a stringent and intensive control programme seems
to be justiﬁed, even for regions or countries with ongoing
CPGN outbreaks or where CPGNs are already endemic.
These control measures should aim for maximum contain-
ment of CPGNs, and must include a multifaceted approach
with different components, as summarized in Table 2. Crucial
to a successful CPGN control programme is a national task
force coordinated and supported by a central public health
authority with competence in hospital infection control. The
aims of this task force are multifaceted and include top pri-
ority action items as listed in Table 3.
As suggested above for the sporadic occurrences, one or
more reference laboratories should play a crucial role in
containing large-scale outbreaks, by providing the services
listed in Table 3.
At the local level, strong commitment on the part of the
hospital administration is necessary to guarantee the success
TABLE 1. Suggested action plan for rapid implementation
of infection control measures in settings with sporadic
occurrence or complete absence of carbapenemase-produc-
ing Gram-negatives
Screening of all patients in contact with an index case
Epidemiological investigation with root cause analysis in cases of nosocomial
cross-transmission events with more than two secondary cases
Measures to keep staff and hospital administration informed
Stringent infection control aimed at containment and ultimate eradication of
nosocomial clusters
Coordination and supervision by public health authorities
TABLE 2. Suggested control measures for countries with
ongoing carbapenemase-producing Gram-negative (CPGN)
outbreaks or endemic CPGNs
At the national level
Establishment of a national task force, supported by the Ministry of Health
Isolation guidelines for carriers—required for all acute-care hospitals
Monthly progress reports about CPGN control for concerned institutions
Evaluation of concerned hospitals and identiﬁcation of problem areas by a
public health agency with competence in infection control
At the hospital level
Physical separation of carriers from non-carriers
Dedicated staff
Active surveillance of high-risk patients
Training and measures to keep staff and hospital administration informed
Ongoing CPGN surveillance with prospective data collection and daily census
of CPGN carriers
TABLE 3. National organizations and their priorities for
action in countries with ongoing carbapenemase-producing
Gram-negative (CPGN) outbreaks or endemic CPGNs
National task force
Policy-making and communication with hospital administrations
Development of stringent and detailed CPGN control guidelines
Preparation of intervention tools
Supervision of control measures and preparation of corrective actions in the
case of ongoing institutional outbreaks without adequate preventive
measures
Active surveillance with rapid feedback at a regional level and national level
Reference laboratories
Conﬁrmation of suspected CPGN cases
Evaluation of molecular epidemiology and establishment of clonality
Detection of new resistance mechanisms
Development of laboratory manuals with descriptions of adequate methods
Quality assurance for clinical microbiology laboratories
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of the aforementioned containment measures, by providing
logistic and ﬁnancial support in close cooperation with the
national task force.
Importantly, infection control measures have to be
adapted to local conditions and speciﬁc hospital sectors, by
taking into account the prevalence and incidence of CPGN
carriage and infection. Training and detailed information has
to be provided to all concerned healthcare workers. Clini-
cians have to be made aware of the problem and should
actively participate in the process, so that routine patient-
care activities can continue without compromising infection
control measures.
Close collaboration with the microbiology laboratory is
crucial, given the need for highly speciﬁc and sensitive CPGN
detection, from both clinical and epidemiological samples,
and for rapid reporting. After an initial containment phase,
each new hospital-acquired case should be investigated in
depth. In order to identify previously known CPGN carriers
and achieve long-term containment of CPGN spread, re-
admission alerts based on electronic ﬁles or chart ﬂagging
are crucial. Information transfer between institutions should
be standard procedure whenever a CPGN patient is trans-
ferred from one hospital to another.
Finally, it is worth underscoring the role of nursing homes
as possible reservoirs of CPGNs [60]. Although data are still
scarce, these institutions are likely to represent for carba-
penemases the same problem recently pointed out for ESBLs
[61]. Studies to assess the prevalence and risk factors for
CPGN carriage are urgently needed, alongside public health
measures addressing the speciﬁc needs of this reservoir pop-
ulation.
Conclusions
Information on how to treat infections with MDR or XDR
CPGNs and how to contain their spread is still surprisingly
limited, in spite of the rapidly increasing prevalence of these
organisms and of their isolation from patients with life-
threatening infections.
Clinical data are still scarce, and they are obtained from
either MBL-producing or KPC-producing isolates (and thus
not applicable to both). The internal diversity of MBLs is
not taken into consideration, as most studies obviously
come from areas where VIM enzymes (with special refer-
ence to VIM-1) are prevalent. Also, data on Enterobacteria-
ceae refer almost exclusively to Klebsiella isolates, and,
although they are likely to be similar (or, at least, not
worse) in E. coli, they do not reﬂect the current diffusion
of carbapenemases among many different Enterobacteriaceae
species. In particular, it is worth bearing in mind that nei-
ther tigecycline nor polymyxin has activity against Proteeae,
among which carbapenemases are being isolated at increas-
ing frequency [62,63].
Limited clinical experience [31,50] and several in vitro syn-
ergy studies [10] (Souli et al., 47th IDSA, 2009, Abstract
218) seem to support the view that antibiotic combinations
should be preferred to monotherapies. But, in light of the
data available to date, it is currently impossible to quantify
the real advantage of drug combinations in the treatment of
these infections.
Comprehensive clinical studies of the main therapeutic
options, broken down by pathogen, enzyme and clinical syn-
drome, are deﬁnitely lacking and, as carbapenemases con-
tinue to spread, are urgently needed. Although any
extrapolation of results from the animal model to humans
calls for great caution, optimal management should include
double or triple combinations of antimicrobials shown to be
synergistic against a given isolate. The best combination is
always strain-dependent, and could include colistin, rifampin,
a carbapenem, or an aminoglycoside.
In the meantime, containment of the spread of CPGNs
essentially relies on implementing strict infection control
measures. Experiences from different countries—chieﬂy
Greece and Israel—have shown that CPGN transmission
and cross-infection can cause a substantial threat to the
healthcare system, with increased adverse outcomes.
Unfortunately, not all hospitals concerned have reacted
adequately and early enough to counter this emerging
threat to public health. Therefore, all European countries
should be made aware of the problem and should have a
preparedness plan ready for implementation at a national
level.
For settings with sporadic occurrence or complete
absence of CPGNs, a preparedness plan should ensure early
detection of ﬁrst cases on the basis of reliable screening
methods, reference laboratories that are prepared for the
conﬁrmation of suspected cases, and active screening of
high-risk patients transferred from countries or institutions
with epidemic or endemic CPGN occurrence. Infection con-
trol measures in these settings should be based on the clas-
sic ‘search and destroy strategy’.
For regions or countries in which CPGNs have become
endemic, stringent control measures should aim for maxi-
mum containment of CPGNs. Although correct implemen-
tation of such measures is presumably cumbersome and
expensive, the huge clinical and public health problems
related to CPGN transmission, alongside the current scar-
city of therapeutic options, seem to fully justify this
choice.
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